Sun Pharma Advanced Research Company Limited has informed the Exchange regarding 'Addendum to Annual Report - Inclusion of Management Discussion & Analysis Report'.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC filed an addendum to its FY25 Annual Report after the Management Discussion & Analysis (MDA) section was inadvertently left out of the version circulated to shareholders on July 18, 2025. The addendum only includes the MDA; the AGM notice and other contents remain unchanged. The MDA covers global and Indian pharma trends, SPARC's strategic shift toward oncology and immunology, and updates on key pipeline assets. Notable clinical news: the PROSEEK trial of Vodobatinib in Parkinson's failed its primary endpoint (program paused), SOLARES Phase 3 trials of Vibozilimod missed primary endpoints, while SBO-154 ADC received USFDA IND clearance and SCD-153 advanced into Phase 1b for Alopecia Areata. Financially, revenue slipped to ₹7,176.60 lakhs (from ₹7,554.53 lakhs) but consolidated net loss narrowed to ₹34,250.94 lakhs (from ₹38,721.39 lakhs); no dividend was declared and the company had 316 employees as of March 31, 2025.
This is mainly an administrative correction with no impact on the AGM notice or financials, though the MDA reveals pipeline setbacks (Vodobatinib, Vibozilimod) that may weigh on sentiment alongside positives like SBO-154's USFDA clearance. With continued losses and negative net worth, SPARC remains dependent on parent SPIL and external funding to sustain R&D.